CLBS Caladrius Biosciences Inc.

-0.13  -4%
Previous Close 3.6
Open 3.59
Price To Book 0.95
Market Cap 35987897
Shares 10,371,152
Volume 3,129
Short Ratio
Av. Daily Volume 30,254

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data did not meet primary endpoint - February 13, 2019.
CLBS03 (The Sanford Project T-Rex Study)
Type 1 diabetes
Announced January 2016 that Phase 3 trial has been discontinued
Metastatic melanoma
Phase 2 data due by the end of 2019 or early 2020.
Coronary microvascular dysfunction (CMD)

Latest News

  1. Caladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results
  2. Caladrius Biosciences announces Purchase Agreement with Lincoln Park Capital for up to $26 million
  3. Caladrius Biosciences to Host 2018 Fourth Quarter and Year End Financial Results Conference Call on Thursday, March 14, 2019 at 4:30 p.m. Eastern Time
  4. What Kind Of Shareholder Appears On The Caladrius Biosciences, Inc.’s (NASDAQ:CLBS) Shareholder Register?
  5. Caladrius Biosciences to Present at the Alliance for Regenerative Medicine 7th Annual Cell & Gene Therapy Investor Day
  6. Caladrius Biosciences Reports Top-Line Data for the Phase 2a Sanford Project: T-Rex Trial of CLBS03 for Recent Onset Type 1 Diabetes
  7. Caladrius Biosciences to Present at Upcoming February Conferences
  8. What Makes Caladrius Biosciences (CLBS) a New Buy Stock
  9. Caladrius Biosciences to Participate in Upcoming January Conferences
  10. Recent Analysis Shows Escalade, Caladrius Biosciences, LightInTheBox Holding Co., Vishay Intertechnology, Ceridian HCM Holding, and Avista Market Influences — Renewed Outlook, Key Drivers of Growth
  11. Caladrius Biosciences to Participate in the Inv€$tival Showcase in Partnership with Jefferies and the Jefferies 2018 London Healthcare Conference
  12. Caladrius Biosciences Reports 2018 Third Quarter Financial Results
  13. Caladrius Biosciences Appoints Cynthia Schwalm to Board of Directors
  14. Caladrius Biosciences to Host Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018 at 4:30 p.m. ET
  15. Caladrius Biosciences Inc (NASDAQ:CLBS): How Does It Impact Your Portfolio?
  16. Caladrius Biosciences (CLBS) Shares March Higher, Can It Continue?
  17. Is Caladrius Biosciences (CLBS) Stock Outpacing Its Medical Peers This Year?